We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Clinical Trial to Prevent New Onset Diabetes After Transplantation (ITP-NODAT)

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01683331
First Posted: September 11, 2012
Last Update Posted: February 23, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Medical University of Vienna
Information provided by (Responsible Party):
Akinlolu Ojo, University of Michigan
  Purpose

Specific Aim 1: To determine the clinical efficacy of early initiation of insulin therapy in decreasing the incidence of NODAT among de novo kidney transplant patients with manifested post-transplant hyperglycemia during the first week after transplantation.

Hypothesis 1: Early initiation of insulin therapy protects beta-cell from early stress related to the surgery and use of higher doses of immunosuppressive medications, and leads to lower incidence of NODAT at 1 and 2 years.

Specific Aim 2: To determine the improvement in overall glycemic control with the early initiation of insulin therapy.

Hypothesis 2: Early initiation of insulin therapy results in greater overall control of glycemia compared to standard care of dietary counseling, life-style modification, oral hypoglycemic agents and/or insulin as needed at 1 year.

Specific Aim 3: To determine the improvement in beta-cell function among patients assigned to the early initiation of insulin therapy at one year post-transplantation.

Hypothesis 3: Early initiation of insulin therapy protects beta-cell from glucotoxicity of post-transplant hyperglycemia and preserves better beta-cell function at 1 year.


Condition Intervention Phase
Prevention of New Onset Diabetes Among Kidney Transplant Patients Drug: Insulin treatment for hyperglycemia Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Clinical Trial to Prevent New Onset Diabetes After Transplantation

Resource links provided by NLM:


Further study details as provided by Akinlolu Ojo, University of Michigan:

Primary Outcome Measures:
  • The incidence of NODAT 12 months after kidney transplantation [ Time Frame: 12 months ]

    NODAT will be defined according to American Diabetes Association definition:

    1. Fasting glucose level equal or greater than 126 mg/dl on two separate blood testings; and/or
    2. 2 hours OGTT values equal or greater than 200 mg/dl; and/or
    3. Glycosylated hemoglobin A1c equal or greater than 6.5; and/or
    4. On oral hypoglycemic agents and/or insulin therapy;


Secondary Outcome Measures:
  • The incidence of NODAT 24 months after kidney transplantation [ Time Frame: 24 months ]

    NODAT will be defined according to American Diabetes Association definition:

    1. Fasting glucose level equal or greater than 126 mg/dl on two separate blood testings; and/or
    2. 2 hours OGTT values equal or greater than 200 mg/dl; and/or
    3. Glycosylated hemoglobin A1c equal or greater than 6.5; and/or
    4. On oral hypoglycemic agents and/or insulin therapy;


Other Outcome Measures:
  • Incidence of impaired fasting glycemia and impaired glucose tolerance 6, 12 and 24 months after transplantation. [ Time Frame: 6, 12 and 24 months ]

    Following American Diabetes Association's definition:

    Impaired fasting glycemia: fasting glucose levels between 100 and 125 mg/dl;

    Impaired glucose tolerance: 2 hours' OGTT values between 140 and 199 mg/dl;



Estimated Enrollment: 300
Actual Study Start Date: August 2012
Estimated Study Completion Date: February 2018
Estimated Primary Completion Date: February 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Insulin treatment for hyperglycemia
Table 1. NPH Insulin Titration Regimen for Patients in Group A Pre-dinner Capillary blood glucose NPH dose initiation (IU/day) NPH dose adjustment(IU/day) > 240 mg/dl 14 Increase by 4 > 180 mg/dl 12 Increase by 4 > 140 mg/dl 10 Increase by 4 > 120 mg/dl 0 Increase by 2 100 to 119 mg/dl 0 Maintain the dose 80 - <100 mg/dl 0 Decrease by 4 60 - <80 mg/dl 0 Decrease by 8 < 60 mg/dl 0 Give ½ of previous dose
Drug: Insulin treatment for hyperglycemia
No Intervention: Standard of care
Patients assigned in this arm will receive standard of care following their kidney transplantation.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Adult patients (> 18 years) with ESRD undergoing kidney transplantation;
  2. Standard triple immunosuppressive medications following kidney transplantation including tacrolimus, mycophenolate moftile and corticosteroids;
  3. Capable to understand the study protocol and to give informed consent;

Exclusion Criteria:

1. Type 1 and 2 DM either as co-morbidity or cause of ESRD;

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01683331


Locations
United States, Michigan
University of Michigan
Ann Arbor, Michigan, United States, 48109
Sponsors and Collaborators
University of Michigan
Medical University of Vienna
Investigators
Principal Investigator: Akinlolu Ojo, MD University of Michigan
  More Information

Responsible Party: Akinlolu Ojo, Emeritus Professor of Medicine, Active, University of Michigan
ClinicalTrials.gov Identifier: NCT01683331     History of Changes
Other Study ID Numbers: 1R01DK092475-01 ( U.S. NIH Grant/Contract )
First Submitted: August 30, 2012
First Posted: September 11, 2012
Last Update Posted: February 23, 2017
Last Verified: February 2017

Keywords provided by Akinlolu Ojo, University of Michigan:
Kidney transplant
New onset diabetes
Prevention
Insulin

Additional relevant MeSH terms:
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin, Globin Zinc
Insulin
Hypoglycemic Agents
Physiological Effects of Drugs